- Cerubidine must be given into a rapidly flowing intravenous infusion. It must never be given by the intramuscular or subcutaneous route. Severe local tissue necrosis will occur if there is extravasation during administration.
- Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure may occur either during therapy or months to years after termination of therapy. The incidence of myocardial toxicity increases after a total cumulative dose exceeding 400 to 550 mg/m2 in adults, 300 mg/m2 in children more than 2 years of age, or 10 mg/kg in children less than 2 years of age.
- Severe myelosuppression occurs when used in therapeutic doses; this may lead to infection or hemorrhage.
- It is recommended that Cerubidine be administered only by physicians who are experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection.
- Dosage should be reduced in patients with impaired hepatic or renal function.
CERUBIDINE (Daunorubicin HCl) FOR INJECTION
Cerubidine (daunorubicin hydrochloride) is the hydrochloride salt of an anthracycline cytotoxic antibiotic produced by a strain of
It is provided as a sterile reddish lyophilized powder in vials for intravenous administration only. Each vial contains 21.4 mg daunorubicin hydrochloride, (equivalent to 20 mg of daunorubicin), and 100 mg mannitol. It is soluble in water when adequately agitated and produces a reddish solution.
Cerubidine in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
Published Studies Related to Cerubidine (Daunorubicin)
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. [2011.02.24]
We conducted a multi-institutional randomized study to determine whether high-dose daunorubicin would be as effective as standard-dose idarubicin in remission-induction therapy for newly diagnosed adult patients younger than 65 years of age with acute myeloid leukemia... Thus, high-dose daunorubicin and standard-dose idarubicin were equally effective for the treatment of adult acute myeloid leukemia, achieving a high rate of complete remission and good long-term efficacy.
Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). [2010.02]
OBJECTIVES: The addition of cladribine to the standard regimen consisting of daunorubicin and cytarabine has been reported to increase the efficacy of induction therapy in acute myeloid leukemia (AML). The goal of this study was to determine the effect of this modification on the incidence and spectrum of infectious complications... CONCLUSIONS: The addition of cladribine to standard induction chemotherapy has no impact on the incidence and spectrum of infectious complications in newly diagnosed AML patients. Copyright 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. [2009.11.10]
PURPOSE: To compare the antitumor efficacy of three different anthracyclines in combination with cytarabine and etoposide in adult patients with newly diagnosed acute myeloid leukemia (AML)... CONCLUSION: In adult patients with AML who do not receive an allogeneic SCT, the use of mitoxantrone or idarubicin instead of daunorubicin enhances the long-term efficacy of chemotherapy.
High-dose daunorubicin in older patients with acute myeloid leukemia. [2009.09.24]
BACKGROUND: A complete remission is essential for prolonging survival in patients with acute myeloid leukemia (AML). Daunorubicin is a cornerstone of the induction regimen, but the optimal dose is unknown. In older patients, it is usual to give daunorubicin at a dose of 45 to 50 mg per square meter of body-surface area... CONCLUSIONS: In patients with AML who are older than 60 years of age, escalation of the dose of daunorubicin to twice the conventional dose, with the entire dose administered in the first induction cycle, effects a more rapid response and a higher response rate than does the conventional dose, without additional toxic effects. (Current Controlled Trials number, ISRCTN77039377; and Netherlands National Trial Register number, NTR212.) 2009 Massachusetts Medical Society
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. [2005.10.15]
To determine whether MDR1 reversal by the addition of the P-glycoprotein (P-gp) inhibitor PSC-833 to standard induction chemotherapy would improve event-free survival (EFS), 419 untreated patients with acute myeloid leukemia (AML) aged 60 years and older were randomized to receive 2 induction cycles of daunorubicin and cytarabine with or without PSC-833...
Clinical Trials Related to Cerubidine (Daunorubicin)
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia [Completed]
Phase I trial to study the effectiveness of combining oblimersen with cytarabine and
daunorubicin in treating older patients who have previously untreated acute myeloid
leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Oblimersen may help cytarabine and daunorubicin kill more
cancer cells by making them more sensitive to chemotherapy.
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML [Recruiting]
The main purpose of this study is to determine the safety of combining selinexor with
daunorubicin and cytarabine. The maximal tolerated dose (MTD) of selinexor with daunorubicin
and cytarabine will also be established.
Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Recruiting]
This phase II trial studies how well daunorubicin hydrochloride, cytarabine, and nilotinib
work in treating patients newly diagnosed with acute myeloid leukemia. Drugs used in
chemotherapy, such as daunorubicin hydrochloride and cytarabine, work in different ways to
stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Nilotinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Giving daunorubicin hydrochloride with cytarabine and nilotinib may
kill more cancer cells.
Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer [Active, not recruiting]
RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the
laboratory may help doctors learn more about how patients respond to treatment with certain
PURPOSE: This laboratory study is looking at the pharmacokinetics of daunorubicin in
treating young patients with cancer.
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome [Recruiting]
The purpose of this study is to see if Panobinostat is safe to give to patients and to
determine the best dose to give in combination with standard cytarabine and daunorubicin
Reports of Suspected Cerubidine (Daunorubicin) Side Effects
Septic Shock (11),
Acute Respiratory Distress Syndrome (9),
Pleural Effusion (7),
Febrile Bone Marrow Aplasia (7),
Generalised Oedema (6),
Bone Marrow Failure (6),
Cytolytic Hepatitis (6), more >>
Page last updated: 2011-12-09